Shares of Regeneron Pharmaceuticals Inc. rallied 3.36% to $591.01 Wednesday, on what proved to be an all-around mixed trading ...

The hits just keep on coming for Regeneron’s Eylea franchise. | The FDA has extended its target action dates for two ...

Regeneron Pharmaceuticals (NASDAQ:REGN) announced that the U.S. FDA has extended the target action dates for two regulatory ...

After an unusual first quarter in which seven of the biopharma industry’s | Several U.S. pharma companies that had posted ...

The Regeneron litigation highlights that donations routed through independent entities are not immune from challenge, especially if the government believes they are effectively covering a patient’s co ...

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large-cap stocks ...

Inspection at Novo Nordisk unit Catalent delays action to Q4 2025, but investors keep faith in Eylea's outlook.

Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug Dupixent, and said it does not expect a material impact from tariffs on ...

Regeneron (REGN) stock in focus as the company surpasses Street's Q2 projections with strong growth in high-dose Eylea, Dupixent, and Libtayo sales. Read more here.

Tarrytown-based Regeneron Pharmaceuticals has reported financial results for its second quarter of 2025. Net revenues increased 4% from the $3.54 ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

While Regeneron's COVID-19 treatment is undoubtedly responsible for the largest drop in sales, even the company's flagship eye medication, Eylea, declined by 2%. In the first quarter of this year ...